Education
About Us
Working with TipRanks
Follow Us
Siegfried Holding AG (SGFEF)
OTHER OTC:SGFEF
RESEARCH TOOLSreports
SGFEF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$885.45 - $1,306.30
Previous CloseN/A
Volume80.00
Average Volume (3M)3.00
Market Cap
$4.83B
Enterprise Value$4.42B
Total Cash (Recent Filing)CHF25.44M
Total Debt (Recent Filing)CHF390.99M
Price to Earnings (P/E)26.1
Beta0.35
Next Earnings
Aug 21, 2025EPS Estimate
21.89Last Dividend Ex-Date
Apr 22, 2025Dividend Yield0.37%
Share Statistics
EPS (TTM)42.00
Shares Outstanding4,523,000
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.62
Price to Book (P/B)N/A
Price to Sales (P/S)2.37
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,275.95Price Target Upside16.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Siegfried Holding AG News
PremiumCompany Announcements
Siegfried Holding AG Shareholders Approve Key Proposals at AGM 2025
PremiumCompany Announcements
Siegfried Holding AG: Profitable Growth Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Financial HealthSFZN's balance sheet is seen as healthy, which supports potential US expansion and merger or acquisition activities.
Market PositionSFZN is positioned to outperform peers due to its strong position in the generics market, especially against competitors facing higher tariffs.
Operational EfficiencyEBITDA margins are anticipated to increase, reflecting a positive outlook on operational efficiency.
Bears Say
Guidance And ExpectationsThe FY25 guidance is typically conservative with limited margin expansion and scope for negative revisions, particularly for EBITDA and a weaker first half of the year.
Profitability ConcernsSFZN will have to target small- and mid-sized pharma for incremental contracts, raising questions about the profitability of producing smaller sales drugs.
Tariff ImpactAnalyst notes that generics are hit harder by tariffs compared to exclusive contracts, potentially impacting profit margins.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
8.37% Mutual Funds
― Other Institutional Investors
86.26% Public Companies and
Individual Investors
SGFEF FAQ
What was Siegfried Holding AG’s price range in the past 12 months?
Siegfried Holding AG lowest stock price was $885.45 and its highest was $1306.30 in the past 12 months.
What is Siegfried Holding AG’s market cap?
Siegfried Holding AG’s market cap is $4.83B.
When is Siegfried Holding AG’s upcoming earnings report date?
Siegfried Holding AG’s upcoming earnings report date is Aug 21, 2025 which is in 116 days.
How were Siegfried Holding AG’s earnings last quarter?
Siegfried Holding AG released its earnings results on Feb 18, 2025. The company reported $24.218 earnings per share for the quarter, missing the consensus estimate of $24.676 by -$0.458.
Is Siegfried Holding AG overvalued?
According to Wall Street analysts Siegfried Holding AG’s price is currently Undervalued.
Does Siegfried Holding AG pay dividends?
Siegfried Holding AG pays a Annually dividend of $4.641 which represents an annual dividend yield of 0.37%. See more information on Siegfried Holding AG dividends here
What is Siegfried Holding AG’s EPS estimate?
Siegfried Holding AG’s EPS estimate is 21.89.
How many shares outstanding does Siegfried Holding AG have?
Siegfried Holding AG has 4,523,000 shares outstanding.
What happened to Siegfried Holding AG’s price movement after its last earnings report?
Siegfried Holding AG reported an EPS of $24.218 in its last earnings report, missing expectations of $24.676. Following the earnings report the stock price went down -6.594%.
Which hedge fund is a major shareholder of Siegfried Holding AG?
Currently, no hedge funds are holding shares in SGFEF
---
Company Description
Siegfried Holding AG
Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral dosage forms, and sterile and aseptic filling injectables, ophthalmics, and inhalative products. It offers contract development and manufacturing services, including pharmaceutical and analytical development, process and analytical transfer, commercial manufacturing and packaging, and scale up and clinical trial material production. In addition, the company provides APIs and controlled substances focusing on anesthetics, pain treatment applications, and central nervous and respiratory diseases. Further, it licenses oral solid and sterile products; assembles registration dossiers; and offers a common technical document for various products. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
---
SGFEF Company Deck
---
SGFEF Earnings Call
Q4 2025
0:00 / 0:00
---
SGFEF Stock 12 Month Forecast
Average Price Target
$1,275.95
▲(16.08% Upside)
Technical Analysis
Lonza Group Ltd
―
Bachem Holding AG
―
PolyPeptide Group AG
―
medmix AG
―
Medartis Holding AG
―
Best Analysts Covering SGFEF
1 Year
1 Year Success Rate
4/4 ratings generated profit
1 Year Average Return
+14.50%
reiterated a buy rating 13 days ago
Copying Tanya Hansalik's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +14.50% per trade.
---